Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Published loading...Updated

Alnylam gets EU approval for Amvuttra in heart disorder treatment

Summary by Seeking Alpha
European Commission approves Alnylam's Amvuttra for hereditary transthyretin amyloidosis with cardiomyopathy. Read more here.

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Monday, June 9, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal